<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148471</url>
  </required_header>
  <id_info>
    <org_study_id>03-0505-A</org_study_id>
    <nct_id>NCT02148471</nct_id>
  </id_info>
  <brief_title>Fatty Acids, Genes and Microbiota in Fatty Liver</brief_title>
  <official_title>Non-alcoholic Steatohepatitis Versus Simple Hepatic Steatosis: Is There a Difference in the Nutritional Factors Influencing Lipid Perioxidation and Inflammation?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johane Allard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Liver Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first aim of this study is to assess oxidative stress and nutritional status in patients
      with elevated liver enzymes who were found to have either simple steatosis (SS) or
      nonalcoholic steatohepatitis (NASH) or normal histological findings on liver biopsy by
      measuring liver lipid peroxides and tumor necrosis factor (TNF)-α, liver pathology and
      immunohistochemistry, liver function tests, liver and red blood cell membrane fatty
      composition, insulin resistance (IR) parameters, plasma lipid peroxides, plasma antioxidant
      vitamins and antioxidant power, lipid profile, subject demographics, medical history and
      medication use. The second aim is to detect differences in hepatic gene expression (messenger
      RNA, mRNA) and epigenetic regulation (micro RNA, miRNA) between patients with SS or NASH and
      healthy controls, in addition to determine in patients with non-alcoholic fatty liver disease
      (NAFLD = SS+NASH combined) whether there is an association between hepatic n-3 PUFA content
      and gene expression. The third aim is to determine the intestinal microbiome (microbial
      composition and metagenome) in patients with SS or NASH and healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NASH is associated with obesity, diabetes and hyperlipidemia. Fat accumulation in the liver
      is likely due to variable degrees of disordered fatty-acid metabolism and insulin resistance
      (IR). Liver steatosis, especially polyunsaturated fatty acids (PUFA) in the liver, increases
      lipid peroxidation and is associated with a reduction in the antioxidant defense system. This
      oxidative stress can lead to increased production of pro-inflammatory cytokines (TNF-α,
      transforming growth factor-beta) contributing to the development of steatohepatitis and
      fibrosis.TNF-α - may further contribute to IR. In addition, changes in fatty acid composition
      within the liver may influence lipid metabolism and inflammation. In particular, n-3 PUFA
      have an effect on the insulin sensitivity, transcription of antioxidant genes, inflammatory
      response and production of reactive oxygen species. Differences might be seen on the gene
      expression level (mRNA) and also in epigenetic regulation (miRNA).

      Microbiota composition might influence energy metabolism, and inflammatory tone and IR
      through increased endotoxemia and therefore could also play a role in the development of
      NAFLD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic fatty acid composition in total lipids in liver biopsy</measure>
    <time_frame>Baseline</time_frame>
    <description>Gas chromatography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic gene expression</measure>
    <time_frame>Baseline</time_frame>
    <description>mRNA by microarray</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal microbiota composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Illumina 16S technology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid peroxides in the liver</measure>
    <time_frame>Baseline</time_frame>
    <description>Test kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic liver antioxidant power</measure>
    <time_frame>Baseline</time_frame>
    <description>Test kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic microRNA expression in the liver</measure>
    <time_frame>Baseline</time_frame>
    <description>NanoString</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota - specific organisms and groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Quantitative real-time polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiome on a genetic level</measure>
    <time_frame>Baseline</time_frame>
    <description>Illumina sequencing technology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-chain fatty acids in stool</measure>
    <time_frame>Baseline</time_frame>
    <description>Gas chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma endotoxin</measure>
    <time_frame>Baseline</time_frame>
    <description>Limulus assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hepatic phospholipid composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Gas chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Red blood cell fatty acid and phospholipid composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Gas chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma fatty acid composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Gas chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma lipid peroxides</measure>
    <time_frame>Baseline</time_frame>
    <description>Test kit</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma antioxidant vitamins</measure>
    <time_frame>Baseline</time_frame>
    <description>Vitamin C colorimetric, alpha- and gamma-tocopherol and beta-carotene by high-performance liquid chromatography</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum antioxidant power</measure>
    <time_frame>Baseline</time_frame>
    <description>Test kit</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF-alpha in the liver</measure>
    <time_frame>Baseline</time_frame>
    <description>Enzyme linked immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunohistochemistry</measure>
    <time_frame>Baseline</time_frame>
    <description>Staining for malondialdehyde, alpha-smooth muscle actin, transforming growth factor beta</description>
  </other_outcome>
  <other_outcome>
    <measure>Free choline in serum</measure>
    <time_frame>Baseline</time_frame>
    <description>liquid chromatography/electrospray ionization-isotope dilution mass spectrometry (LC/ESI-IDMS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Bacterial DNA in plasma</measure>
    <time_frame>Baseline</time_frame>
    <description>Quantitative polymerase chain reaction for bacterial 16S rDNA</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting glucose and insulin to calculate insulin resistance (HOMA-IR), C-peptide, hemoglobin A1c, all by standard laboratory methods</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma ethanol</measure>
    <time_frame>Baseline</time_frame>
    <description>standard laboratory measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Baseline</time_frame>
    <description>Weight, height, skinfolds, bioelectrical impedance analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Food intake</measure>
    <time_frame>Baseline</time_frame>
    <description>7-day food records</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>Baseline</time_frame>
    <description>7 day activity logs</description>
  </other_outcome>
  <other_outcome>
    <measure>Factors influencing intestinal microbiota</measure>
    <time_frame>Baseline</time_frame>
    <description>Environmental questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver function tests</measure>
    <time_frame>Baseline</time_frame>
    <description>Alanine transaminase, aspartate transaminase, alkaline phosphatase, standard laboratory tests</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">205</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <condition>Steatosis</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy living liver donors with healthy liver on imaging and/or liver histology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simple steatosis</arm_group_label>
    <description>Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonalcoholic steatohepatitis</arm_group_label>
    <description>Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal findings</arm_group_label>
    <description>Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA - samples retained, with potential for extraction of DNA from at least one of the types
      of samples retained (e.g., frozen tissue, whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy living liver donors from the Multiorgan transplant program at the University Health
        Network Patients with nonalcoholic fatty liver disease (SS or NASH on liver biopsy) or
        patients with elevated liver enzymes but no significant findings on liver biopsy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female patients, age &gt;18 y

          -  A liver biopsy with a diagnosis of SS or NASH OR No signs of steatosis, fibrosis or
             any other kind of liver disease on histology (minimal findings) OR For healthy control
             subjects, those with normal liver enzymes and normal liver imaging on ultrasound

          -  alcohol consumption (&lt;20g of ethanol per day);

          -  absence of any other possible cause for liver dysfunction.

        Exclusion criteria:

          -  any other liver disease apart from NAFLD

          -  anticipated need for liver transplantation in one year or complications of liver
             disease;

          -  any reasons contraindicating a liver biopsy (patients) or liver donation (healthy
             donors)

          -  chronic gastrointestinal diseases, previous gastrointestinal surgery modifying the
             anatomy, patients with diabetes requiring insulin.

          -  medications known to precipitate steatohepatitis (corticosteroids, high dose
             estrogens, methotrexate, amiodarone, spironolactone, sulfasalazine, perhexiline
             maleate, diethylamino- ethoxyhexestrol (DH), tamoxifen, diethylstilbestrol, naproxen
             or oxacillin) or regular intake of non-steroidal anti-inflammatory drugs (except for
             low dose aspirin), use of ursodeoxycholic acid or any experimental drug in the 6
             months prior to entry.

          -  regular intake of prebiotics, probiotics, antibiotics, or laxatives; in the 3 months
             prior to study entry

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johane Allard, MD,FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Feb 21;20(7):1712-23. doi: 10.3748/wjg.v20.i7.1712. Review.</citation>
    <PMID>24587650</PMID>
  </reference>
  <reference>
    <citation>Monteiro J, Leslie M, Moghadasian MH, Arendt BM, Allard JP, Ma DW. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 2014 Mar;5(3):426-35. doi: 10.1039/c3fo60551e. Review.</citation>
    <PMID>24496399</PMID>
  </reference>
  <reference>
    <citation>Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2012 Jul;46(6):457-67. doi: 10.1097/MCG.0b013e31824cf51e. Review.</citation>
    <PMID>22469640</PMID>
  </reference>
  <reference>
    <citation>Mouzaki M, Allard J. Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Ann Gastroenterol. 2012;25(3):207-217. Review.</citation>
    <PMID>24713803</PMID>
  </reference>
  <results_reference>
    <citation>Da Silva HE, Arendt BM, Noureldin SA, Therapondos G, Guindi M, Allard JP. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet. 2014 Aug;114(8):1181-94. doi: 10.1016/j.jand.2014.01.009. Epub 2014 Mar 14.</citation>
    <PMID>24631112</PMID>
  </results_reference>
  <results_reference>
    <citation>Arendt BM, Ma DW, Simons B, Noureldin SA, Therapondos G, Guindi M, Sherman M, Allard JP. Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl Physiol Nutr Metab. 2013 Mar;38(3):334-40. doi: 10.1139/apnm-2012-0261. Epub 2012 Oct 15.</citation>
    <PMID>23537027</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013 Jul;58(1):120-7. doi: 10.1002/hep.26319. Epub 2013 May 14.</citation>
    <PMID>23401313</PMID>
  </results_reference>
  <results_reference>
    <citation>Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008 Feb;48(2):300-7. Epub 2007 Nov 20.</citation>
    <PMID>18086506</PMID>
  </results_reference>
  <results_reference>
    <citation>Arendt BM, Comelli EM, Ma DW, Lou W, Teterina A, Kim T, Fung SK, Wong DK, McGilvray I, Fischer SE, Allard JP. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015 May;61(5):1565-78. doi: 10.1002/hep.27695. Epub 2015 Feb 27.</citation>
    <PMID>25581263</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Johane Allard</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Nonalcoholic fatty liver disease</keyword>
  <keyword>Steatosis</keyword>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

